ARID2 and hepatocellular carcinoma: Our CRISPR‐mediated knock‐out for the ARID2 gene provided evidence that the NER process is disrupted through inhibition of the recruitment of XPG, resulting in susceptibility to carcinogens and potential hypermutation in the ARID2‐mutated subtype of HCC.